Vasoplegia in a Patient Whose Own ACE Inhibitor May Be Working Against the Fix
A 67-year-old man on chronic lisinopril develops refractory vasoplegia after a long bypass run. The drug most likely to help him works through the same pathway his home medication has spent years suppressing.
Harold B., a 67-year-old man, has taken lisinopril for hypertension for the better part of fifteen years, tightly controlled and unremarkable until an echocardiogram ordered for unrelated shortness of breath found severe mitral regurgitation from a flail posterior leaflet — degenerative disease, not ischemic, and repairable rather than requiring replacement per his surgeon's assessment going in. His lisinopril was held the morning of surgery per routine protocol, which is worth stating plainly because holding one dose does not undo fifteen years of renin-angiotensin suppression: the vascular tone he brings into the operating room is the tone that system has settled into over a decade and a half, not the tone of a patient who simply took a pill this morning.
His bypass run for the repair went longer than typical, closer to three hours given the technical complexity of the leaflet resection and annuloplasty, and coming off bypass his blood pressure will not hold despite escalating norepinephrine — a mean arterial pressure sitting in the 40s on a dose that would ordinarily be more than adequate. His cardiac index on TEE is preserved, which is the finding that makes this a resistance problem rather than a pump problem and takes the reflexive inotrope off the table before anyone reaches for it. This is the recognizable picture of vasoplegic syndrome, a real and reasonably common complication of longer bypass runs, but two features of his case make the next step less straightforward than escalating norepinephrine further. First, his chronic ACE inhibitor use is itself a described risk factor for refractory, harder-to-treat vasoplegia after cardiac surgery — which may be why he is here at all. Second, and more specifically relevant to what happens next, that same long-standing angiotensin-II suppression may bear on which rescue agent is likely to work, since the leading options act through pathways that do not sit equally well alongside years of a suppressed renin-angiotensin axis.
Norepinephrine climbing, pressure still not holding
Methylene blue next. It's the most established rescue agent we have for this picture, and the whole team already knows how to dose and monitor it safely. I don't see a reason to reach for something less familiar before we've tried the option with the longer track record.
I'd go straight to hydroxocobalamin instead, and it's specifically because of his lisinopril. Chronic ACE inhibition is a real, described risk factor for refractory vasoplegia — which may be exactly why he's here — and methylene blue works by blocking the nitric oxide-guanylate cyclase pathway.
Years of suppressed angiotensin-II-driven vascular tone may have left him more dependent on that nitric oxide pathway for whatever residual vasoconstriction he has left. Blocking it with methylene blue in a patient who may already be leaning on it more than usual could plausibly blunt the drug's own effectiveness in exactly the population where vasoplegia is most likely to occur.
I want to be honest about how strong that argument actually is — the ACE-inhibitor-vasoplegia association is real, but I don't think the literature has actually shown methylene blue works worse in that subgroup specifically, only that the subgroup is more likely to develop vasoplegia in the first place. Those aren't the same claim, and I don't want us picking an agent based on a mechanistic story that outruns the actual evidence.
That said, his pressure isn't holding and we don't have time to relitigate this at length. Given genuine uncertainty either way, and hydroxocobalamin's own real track record as an effective rescue agent, I'm willing to go with your recommendation — not because I'm convinced the mechanism argument is decisive, but because I don't have a confident basis to insist on methylene blue over it.
Agreed: hydroxocobalamin given at 5g IV, norepinephrine continued unchanged alongside it. MAP improved to the 60s within fifteen minutes, allowing norepinephrine to be weaned over the following hour.
Not agreed as a settled mechanism: whether hydroxocobalamin's apparent effectiveness here actually confirms the ACE-inhibitor-nitric-oxide-pathway concern, or whether he simply would have responded to either agent and the team will never know which explanation is correct from a single case. The cardiac anesthesiologist's caution about outrunning the evidence was not retracted even after the good response — both voices agreed one case doesn't resolve the underlying uncertainty either way.